Abstract:Despite success in vaccinating populations against SARS-CoV-2, concerns about immunity duration, continued efficacy against emerging variants, protection from infection and transmission, and worldwide vaccine availability remain. Molecular adjuvants targeting pattern recognition receptors (PRRs) on antigen-presenting cells (APCs) could improve and broaden the efficacy and durability of vaccine responses. Native SARS-CoV-2 infection stimulates various PRRs, including toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors. We hypothesized that targeting PRRs using molecular adjuvants on nanoparticles (NPs) along with a stabilized spike protein antigen could stimulate broad and efficient immune responses. Adjuvants targeting TLR4 (MPLA), TLR7/8 (R848), TLR9 (CpG), and RIG-I (PUUC) delivered on degradable polymer NPs were combined with the S1 subunit of spike protein and assessed in vitro with isogeneic mixed lymphocyte reactions (isoMLRs). For in vivo studies, the adjuvant-NPs were combined with stabilized spike protein or spike-conjugated NPs and assessed using a two-dose intranasal or intramuscular vaccination model in mice. Combination adjuvant-NPs simultaneously targeting TLR and RIG-I receptors (MPLA+PUUC, CpG+PUUC, and R848+PUUC) differentially induced T cell proliferation and increased proinflammatory cytokine secretion by APCs in vitro. When delivered intranasally, MPLA+PUUC NPs enhanced CD4+CD44+ activated memory T cell responses against spike protein in the lungs while MPLA NPs increased anti-spike IgA in the bronchoalveolar (BAL) fluid and IgG in the blood. Following intramuscular delivery, PUUC NPs induced strong humoral immune responses, characterized by increases in anti-spike IgG in the blood and germinal center B cell populations (GL7+ and BCL6+ B cells) in the draining lymph nodes (dLNs). MPLA+PUUC NPs further boosted spike protein-neutralizing antibody titers and T follicular helper cell populations in the dLNs. These results suggest that protein subunit vaccines with particle-delivered molecular adjuvants targeting TLR4 and RIG-I could lead to robust and unique route-specific adaptive immune responses against SARS-CoV-2.

Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.

Recombinant<i>Ov</i>-ASP-1, a Th1-Biased Protein Adjuvant Derived from the Helminth<i>Onchocerca volvulus</i>, Can Directly Bind and Activate Antigen-Presenting Cells

Rov-Asp-1, a Recombinant Secreted Protein of the Helminth Onchocercavolvulus, is a Potent Adjuvant for Inducing Antibodies to Ovalbumin, HIV-1 Polypeptide and SARS-CoV Peptide Antigens

The Adjuvanticity of an O. Volvulus-Derived Rov-Asp-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates

A Truncated Fragment of Ov-Asp-1 Consisting of the Core Pathogenesis-Related-1 (Pr-1) Domain Maintains Adjuvanticity As the Full-Length Protein

IL-17 As an Adjuvant Enhances Immune Responses of Recombinant Protein Vaccine

Adjuvant effect of ginsenoside Rg1

Novel Polysaccharide Adjuvant from the Roots of Actinidia Eriantha with Dual Th1 and Th2 Potentiating Activity.

Orf virus as an adjuvant enhances the immune response to a PCV2 subunit vaccine

Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation

Priming with Raav Encoding Rbd of Sars-Cov S Protein and Boosting with Rbd-Specific Peptides for T Cell Epitopes Elevated Humoral and Cellular Immune Responses Against Sars-Cov Infection

Adjuvant effect of two polysaccharides from the petals of Crocus sativus and its mechanisms

Ginsenoside Rg1 Enhances Immune Response Induced by Recombinant Toxoplasma Gondii SAG1 Antigen.

Induction of Protection Against Divergent H5N1 Influenza Viruses Using a Recombinant Fusion Protein Linking Influenza M2e to Onchocerca Volvulus Activation Associated Protein-1 (ASP-1) Adjuvant

Phosphorothioated Antisense Oligodeoxynucleotide Suppressing Interleukin-10 is a Safe and Potent Vaccine Adjuvant.

Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response

[Immune Response Induced by Vaccination with Pseudotyped Raav1 Expressing HPV16 L1 Protein].

Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity

A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines

Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine

Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.